American Society of Clinical Oncology Annual Meeting (ASCO) | Conference

Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer
June 08, 2021

Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.

Larotrectinib Is Efficacious and Tolerable in NTRK-Fusion Positive CNS Tumors
June 07, 2021

Data from 2 clinical trials proved that larotrectinib is efficacious and safe in treating adults and children with NTRK fusion-positive central nervous system cancers.

Pediatric Patients With RET-Altered Tumors Experience Tumor Responses With Selpercatinib
June 07, 2021

Evidence of preliminary activity was noted with the use of the RET inhibitor selpercatinib in pediatric patients with solid tumors harboring RET alterations.